NGY B
Alternative Names: NGY-BLatest Information Update: 18 Jan 2022
At a glance
- Originator Nirogy Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Monocarboxylic acid transporter inhibitors; Solute carrier protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 12 Jan 2022 Nirogy Therapeutics plans to file IND for Cancer in next 12 months
- 10 Apr 2021 Pharmacodynamics data from a preclinical studies in Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 23 Jan 2021 Nirogy therapeutics receives SBIR grant from the National Institute of Health and National Cancer Institute for dual monocarboxylate transporter 1 and 4 inhibitors for Breast cancer